306 related articles for article (PubMed ID: 37046760)
1. Targeting the Molecular and Immunologic Features of Leiomyosarcoma.
Cope BM; Traweek RS; Lazcano R; Keung EZ; Lazar AJ; Roland CL; Nassif EF
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046760
[TBL] [Abstract][Full Text] [Related]
2. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
5. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
6. Pleomorphic Undifferentiated Uterine Sarcoma in a Young Patient Presenting With Elevated Beta-hCG and Rare Variants of Benign Leiomyoma: A Case Report and Review of the Literature.
Krishnan V; Sauthier P; Provencher D; Rahimi K
Int J Gynecol Pathol; 2020 Jul; 39(4):362-366. PubMed ID: 31033798
[TBL] [Abstract][Full Text] [Related]
7. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
8. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.
Agaram NP; Zhang L; LeLoarer F; Silk T; Sung YS; Scott SN; Kuk D; Qin LX; Berger MF; Antonescu CR; Singer S
Genes Chromosomes Cancer; 2016 Feb; 55(2):124-30. PubMed ID: 26541895
[TBL] [Abstract][Full Text] [Related]
9. Leiomyosarcoma of the urinary bladder: A SEER database study and comparison to leiomyosarcomas of the uterus and extremities/trunk.
Coiner BL; Cates J; Kamanda S; Giannico GA; Gordetsky JB
Ann Diagn Pathol; 2021 Aug; 53():151743. PubMed ID: 33964611
[TBL] [Abstract][Full Text] [Related]
10. The Future of Targeted Therapy for Leiomyosarcoma.
Denu RA; Dann AM; Keung EZ; Nakazawa MS; Nassif Haddad EF
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473300
[TBL] [Abstract][Full Text] [Related]
11. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.
Cui RR; Wright JD; Hou JY
BJOG; 2017 Jun; 124(7):1028-1037. PubMed ID: 28128524
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of tumor-associated macrophages in leiomyosarcoma: a single institution study.
Ganjoo KN; Witten D; Patel M; Espinosa I; La T; Tibshirani R; van de Rijn M; Jacobs C; West RB
Am J Clin Oncol; 2011 Feb; 34(1):82-6. PubMed ID: 23781555
[TBL] [Abstract][Full Text] [Related]
13.
Williams EA; Sharaf R; Decker B; Werth AJ; Toma H; Montesion M; Sokol ES; Pavlick DC; Shah N; Williams KJ; Venstrom JM; Alexander BM; Ross JS; Albacker LA; Lin DI; Ramkissoon SH; Elvin JA
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015533
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN.
Guo X; Li S; Tong H; Zhang Y; Ji Y; Zhuang R; Zhang C; You Y; Lu W; Zhou Y
Front Oncol; 2022; 12():802074. PubMed ID: 35237514
[TBL] [Abstract][Full Text] [Related]
15. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.
Hemming ML; Fan C; Raut CP; Demetri GD; Armstrong SA; Sicinska E; George S
Mol Cancer Res; 2020 Sep; 18(9):1302-1314. PubMed ID: 32518213
[TBL] [Abstract][Full Text] [Related]
17. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic advances in leiomyosarcoma.
Lacuna K; Bose S; Ingham M; Schwartz G
Front Oncol; 2023; 13():1149106. PubMed ID: 36969049
[TBL] [Abstract][Full Text] [Related]
19. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease.
Hemming ML; Klega KS; Rhoades J; Ha G; Acker KE; Andersen JL; Thai E; Nag A; Thorner AR; Raut CP; George S; Crompton BD
JCO Precis Oncol; 2019; 2019():. PubMed ID: 30793095
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
Hemming ML; Bhola P; Loycano MA; Anderson JA; Taddei ML; Doyle LA; Lavrova E; Andersen JL; Klega KS; Benson MR; Crompton BD; Raut CP; George S; Letai A; Demetri GD; Sicinska E
Clin Cancer Res; 2022 Jun; 28(11):2397-2408. PubMed ID: 35325095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
